RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mochida Pharmaceutical Co Stock

Mochida Pharmaceutical Co P/E 2024

Mochida Pharmaceutical Co P/E

23.94

Ticker

4534.T

ISIN

JP3922800002

WKN

859288

As of Sep 10, 2024, Mochida Pharmaceutical Co's P/E ratio was 23.94, a 28.43% change from the 18.64 P/E ratio recorded in the previous year.

The Mochida Pharmaceutical Co P/E history

Mochida Pharmaceutical Co Aktienanalyse

What does Mochida Pharmaceutical Co do?

Mochida Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company has been in the industry for over 100 years and has become one of the leading providers of medications and health products in Japan and worldwide. The history of Mochida Pharmaceutical begins in 1913 when Shoyo Mochida founded the company. Initially, the company specialized in the production of vitamins and later expanded its product range to include other pharmaceutical products. Over the following decades, the company steadily grew and expanded internationally. Today, Mochida Pharmaceutical is involved in various areas of healthcare. The company offers a wide range of medications for the treatment of various diseases and ailments, including cardiovascular diseases, diabetes, cancer, infectious diseases, and mental illnesses. Mochida Pharmaceutical is also involved in other areas of healthcare. The company manufactures and distributes various medical devices and diagnostics, including a wide range of medical instruments such as endoscopes and ultrasound devices, as well as tests and reagents for the diagnosis of infectious diseases and other conditions. A major focus of Mochida Pharmaceutical's business model is research and development of new products. The company has an extensive research and development department that continuously works on the development of new medications and technologies. Mochida Pharmaceutical collaborates closely with various universities and research institutes to develop new insights and technologies. In addition to the production and distribution of medications and medical devices, Mochida Pharmaceutical is also engaged in health promotion and prevention. The company offers various health services and products aimed at helping people live healthier lives and take better care of their health. Over the years, the company has achieved several important milestones. In 1970, Mochida Pharmaceutical successfully developed an immunosuppressive medication that is now known as Tacrolimus and is used to prevent organ transplant rejection. Other significant milestones include the introduction of medications for the treatment of diabetes and cancer, as well as the development of new technologies such as transdermal patches for medication administration. Mochida Pharmaceutical is now a globally operating company with branches in various countries. The company employs thousands of employees worldwide and has a strong presence in all major markets. The company is committed to further expanding its position as a leading provider of medical products and services and focusing on the needs of its customers and patients. Mochida Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Mochida Pharmaceutical Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Mochida Pharmaceutical Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Mochida Pharmaceutical Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Mochida Pharmaceutical Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Mochida Pharmaceutical Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Mochida Pharmaceutical Co stock

What is the price-to-earnings ratio of Mochida Pharmaceutical Co?

The price-earnings ratio of Mochida Pharmaceutical Co is currently 23.94.

How has the price-earnings ratio of Mochida Pharmaceutical Co changed compared to last year?

The price-to-earnings ratio of Mochida Pharmaceutical Co has increased by 28.43% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mochida Pharmaceutical Co high compared to other companies?

Yes, the price-to-earnings ratio of Mochida Pharmaceutical Co is high compared to other companies.

How does an increase in the price-earnings ratio of Mochida Pharmaceutical Co affect the company?

An increase in the price-earnings ratio of Mochida Pharmaceutical Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mochida Pharmaceutical Co affect the company?

A decrease in the price-earnings ratio of Mochida Pharmaceutical Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mochida Pharmaceutical Co?

Some factors that influence the price-earnings ratio of Mochida Pharmaceutical Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mochida Pharmaceutical Co pay?

Over the past 12 months, Mochida Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 2.42 %. For the coming 12 months, Mochida Pharmaceutical Co is expected to pay a dividend of 83.96 JPY.

What is the dividend yield of Mochida Pharmaceutical Co?

The current dividend yield of Mochida Pharmaceutical Co is 2.42 %.

When does Mochida Pharmaceutical Co pay dividends?

Mochida Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Mochida Pharmaceutical Co?

Mochida Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Mochida Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 83.96 JPY are expected. This corresponds to a dividend yield of 2.54 %.

In which sector is Mochida Pharmaceutical Co located?

Mochida Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mochida Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mochida Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Mochida Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Mochida Pharmaceutical Co in the year 2023?

In the year 2023, Mochida Pharmaceutical Co distributed 80 JPY as dividends.

In which currency does Mochida Pharmaceutical Co pay out the dividend?

The dividends of Mochida Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mochida Pharmaceutical Co

Our stock analysis for Mochida Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mochida Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.